Beleodaq®

Onxeo announces compelling preclinical data in combination for its two innovative compounds, AsiDNA™ and belinostat

Results demonstrate a very strong synergistic effect between AsiDNA™,  first-in-class DNA break repair inhibitor (DBRi), and histone deacetylase inhibitors (HDACi) This synergy is particularly high for the combination of  its two proprietary assets, AsiDNA™ and belinostat, Potential application of AsiDNA™ in combination with any HDACi fully covered by a key worldwide patent application   Paris (France), September 28, 2017 –…read more →

Clinigen and Onxeo initiate Managed Access programme for belinostat in Europe for patients with peripheral T-cell lymphoma (PTCL)

Paris, April 24, 2017 – 18 :30 CEST. Clinigen Group plc’s (AIM: CLIN, ‘Clinigen’ or the ‘Group’) Idis Managed Access (MA) division and Onxeo S.A (Euronext Paris, Nasdaq Copenhagen: ONXEO, ‘Onxeo’), have agreed to launch a Managed Access programme for belinostat (Beleodaq®) in Europe. Belinostat is for use in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). PTCL is a…read more →

Onxeo Announces Promising Results from Preclinical Study of Beleodaq® Combination with Checkpoint Inhibitors

Combination with checkpoint inhibitors decreased tumor growth rate and prolonged survival in syngeneic HCC mouse model Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced promising results from preclinical studies evaluating the potential of its already…read more →

Onxeo Signs Exclusive License Agreement with Pint Pharma for the Commercialization of Beleodaq® in PTCL in South America

Agreement covering seven South American countries Onxeo to receive upfront payment, regulatory and commercial milestones, and sales royalties for a total deal value greater than USD 20 million Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specialized in the development of orphan oncology therapeutics, today announced it has entered into an exclusive license agreement…read more →

Onxeo collaborates with the Royal College of Surgeons in Ireland for research program on Beleodaq® derivatives // DANISH TRANSLATION: Onxeo samarbejder med Royal College of Surgeons i Irland om forskningsprogram vedrørende derivater af Beleodaq®

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced a collaboration with the Royal College of Surgeons in Ireland (RCSI) for a discovery-stage program on the derivatives of belinostat (Beleodaq®), a histone deacetylase (HDAC) inhibitor. This new collaboration program aims…read more →

Onxeo announces development of Beleodaq® oral formulation opening new opportunities for its HDAC inhibitor // DANISH TRANSLATION: Onxeo offentliggør udviklingen af en oral formulering af Beleodaq®, som åbner nye muligheder for selskabets HDAC-hæmmer

NB! FOR DANISH TRANSLATION, SCROLL DOWN. The company has obtained the first set of positive results of PK study with new oral formulation of Beleodaq®  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced the first set of positive results from a preclinical pharmacokinetic (PK)…read more →

Onxeo expands collaborations to advance development program of key orphan oncology assets in combination with immuno-oncology agents // DANISH TRANSLATION: Onxeo udvider sine samarbejdsaftaler for at videreudvikle sit program med væsentlige aktiver inden for sjældne kræftsygdomme i kombination med immune-onkologiske stoffer

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Following first positive results already obtained  in several types of tumors  New partnership with CIMA’s Immunology Program and the Liver Unit at Clinica Universidad de Navarra in Spain under the leadership of Prof. B. Sangro Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan…read more →

Spectrum Pharmaceuticals and Onxeo announce complete response in 67% of patients with peripheral T-cell lymphoma in combination of belinostat (Beleodaq®) and standard CHOP // DANISH TRANSLATION: Onxeo og Spectrum Pharmaceuticals offentliggør, at der er opnået komplet respons hos 67 % af patienterne med perifert T-celle lymfekræft (PTCL) med kombinationen af belinostat (Beleodaq®) og standard CHOP-behandling

Data was Highlighted in an Oral Presentation of a Phase 1 Study at the 57th Annual Meeting of the American Society of Hematology (ASH) Study Shows 86% Objective Response Rate with 67% Complete Responses in Newly Diagnosed Patients with Peripheral T-cell Lymphoma (PTCL) At Full Dose Intensity the Belinostat-CHOP Combination was Well-Tolerated HENDERSON, Nev. and PARIS (France), COPENHAGEN (Denmark) –…read more →

Onxeo initiates comprehensive strategy to extend value of key orphan oncology assets // DANISH TRANSLATION: Onxeo indleder omfattende strategiplan for at øge værdien af selskabets vigtigste lægemidler til behandling af sjældne kræftsygdomme

Currently exploring combinations for synergistic effect to identify new indications for Livatag® and Beleodaq® Signed two collaborations with Lyon’s University Hospital and Synovo’s immuno-oncology specialists  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, announced the initiation of a comprehensive strategy to explore further potential indications…read more →

Onxeo Reports Initial Results of Phase 1 Trial Evaluating Belinostat in Combination with CHOP in Peripheral T-cell Lymphoma (PTCL) — Onxeo rapporterer foreløbige resultater fra fase I-studiet til evaluering af belinostat i kombination med CHOP-behandling mod perifert T-celle lymfekræft (PTCL)

Full results to be reported in Oral Presentation at 2015 ASH (American Society of Hematology) Annual Meeting Data demonstrate 89% objective response rate, 72% complete response rate, and good safety profile of belinostat in combination with CHOP Study supports the interest of belinostat in combination with CHOP as first-line treatment for PTCL Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext…read more →

Beleodaq® (belinostat) pivotal BELIEF study results published in the Journal of Clinical Oncology (JCO) – Resultater fra det pivotale BELIEF-studie med Beleodaq® (belinostat) publiceret i Journal of Clinical Oncology (JCO)

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced the publication of results from the pivotal BELIEF (PXD101-CLN-19) study which was selected as a Rapid Communication in the Journal of Clinical Oncology (JCO), the journal of the American Society of Clinical Oncology.  The JCO is peer-reviewed and is one…read more →

Onxeo Announces Preclinical & Clinical Data from Three Studies Supporting the Potential For Belinostat in Multiple Orphan Oncology Indications – Onxeo offentliggør prækliniske og kliniske data fra tre studier, som understøtter potentialet for belinostat i en række sjældne kræftindikationer

Findings provide key validation; help identify target indications for optimal development Data demonstrating safety and efficacy to be presented at ASCO Annual Meeting 2015 on Sunday, May 31 Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced preclinical & clinical data from three studies supporting of the potential of…read more →

Belinostat abstracts for American Association for Cancer Research 2015 – Abstracts om belinostat på 2014 årsmødet i American Association for Cancer Research

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that preclinical and clinical data on belinostat will be presented at the 2015 American Association for Cancer Research (AACR) Annual Meeting (April 18-22, 2015) in Philadelphia (Pennsylvania), USA. Preclinical and clinical abstracts involving belinostat will be featured at the AACR…read more →

Belinostat phase I/II results in soft tissue sarcoma to be presented at the 2015 Annual ASCO Meeting — Fase I/II-resultater for belinostat til behandling af bløddelssarkom præsenteres på ASCO 2015 årsmødet

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that the phase I/II clinical trial of belinostat in combination with doxorubicin (PXD101-CLN-14) in patients with soft tissue sarcoma (STS) was accepted for presentation in the Poster Discussion Session at the 2015 Annual Meeting of the American Society of Clinical…read more →

Onxeo confirms receipt of the $25M milestone payment on Beleodaq® – Onxeo bekræfter modtagelsen af milepælsbetaling på USD 25 mio. for Beleodaq®

Onxeo SA (Euronext Paris, NASDAQ OMX Copenhagen – ONXEO), an innovative company specializing in the development of orphan oncology drugs, announces that it has received from his US partner Spectrum Pharmaceuticals the milestone payment of $25 million related to the approval of Beleodaq® by the FDA. Early July 2014, Beleodaq® was granted by the U.S. Food and Drug Administration (FDA)…read more →

12